3-(1-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-4-piperidinyl)-4,4-dimethyl-1,3-oxazolidin-2-one | 1237840-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-(1-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-4-piperidinyl)-4,4-dimethyl-1,3-oxazolidin-2-one
• 英文别名: 3-[1-[3-chloro-6-(furan-3-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carbonyl]piperidin-4-yl]-4,4-dimethyl-1,3-oxazolidin-2-one
• CAS: 1237840-71-9
• 化学式: C₂₃H₂₂ClF₃N₄O₄
• 分子量: 510.9
• InChiKey: FMXUHYHZGJXUNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-氨基-3-三氟甲基-5-溴吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 N-氯代丁二酰亚胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 1.0h， 生成 3-(1-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-4-piperidinyl)-4,4-dimethyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization

  摘要：

  A series of imidazo[1,2-a]pyridines which directly bind to HCV Non-Structural Protein 4B (NS4B) is described. This series demonstrates potent in vitro inhibition of HCV replication (EC50 < 10 nM), direct binding to purified NS4B protein (IC50 < 20 nM), and an HCV resistance pattern associated with NS4B (H94N/R, V105L/M, F98L) that are unique among reported HCV clinical assets, suggestive of the potential for additive or synergistic combination with other small molecule inhibitors of HCV replication.

  DOI：

  10.1021/ml300090x

文献信息

• [EN] PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE PIPÉRIDINYLE AMIDO CYCLIQUE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010091411A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是式（I）的化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒介导的病毒感染，如丙型肝炎病毒（HCV）。
• Piperidinyl Cyclic Amido Antiviral Agents
  申请人：Baskaran Subramanian

  公开号：US20100272680A1

  公开（公告）日：2010-10-28

  Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是化合物I式及其药物可接受的盐，它们的药物组合物，它们的制备方法以及它们用于治疗由黄病毒科病毒成员介导的病毒感染，例如丙型肝炎病毒（HCV）的用途。
• Imidazo[1,2-<i>a</i>]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization
  作者：J. Brad Shotwell、Subramanian Baskaran、Pek Chong、Katrina L. Creech、Renae M. Crosby、Hamilton Dickson、Jing Fang、Dulce Garrido、Amanda Mathis、Jack Maung、Derek J. Parks、Jeffrey J. Pouliot、Daniel J. Price、Roopa Rai、John W. Seal、Uli Schmitz、Vincent W. F. Tai、Michael Thomson、Mi Xie、Zhiping Z. Xiong、Andrew J. Peat

  DOI：10.1021/ml300090x

  日期：2012.7.12

  A series of imidazo[1,2-a]pyridines which directly bind to HCV Non-Structural Protein 4B (NS4B) is described. This series demonstrates potent in vitro inhibition of HCV replication (EC50 < 10 nM), direct binding to purified NS4B protein (IC50 < 20 nM), and an HCV resistance pattern associated with NS4B (H94N/R, V105L/M, F98L) that are unique among reported HCV clinical assets, suggestive of the potential for additive or synergistic combination with other small molecule inhibitors of HCV replication.